Company intelligence / Profile preview
Frontier Medicines
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
Overview
Frontier Medicines has developed a proprietary drug discovery platform that combines chemoproteomics, covalent chemistry, and machine learning to identify new binding pockets on previously undruggable proteins. Their lead program targets both active and inactive forms of KRAS G12C mutations implicated in several cancers. Early data suggest the approach may overcome resistance seen with existing single-target inhibitors. The company has a deep pipeline focused on high-impact oncology targets and a major partnership with AbbVie for additional programs.[3][4][5]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesProtein degraders (targeted protein degradation)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Frontier Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Frontier Medicines.